180 likes | 251 Views
This program focuses on training and capacity building activities to enhance essential medicines and policy standards in WHO Prequalification Programme. It offers support to manufacturers, CROs, QCLs, and NRAs on GMP compliance, dossier compilation, and QC laboratory practices. The initiative encourages submissions to the Prequalification Programme, with training sessions covering topics like GMP principles, pharmaceutical formulations, and prequalification specifics tailored to different therapeutic areas.
E N D
Trainings and capacity building activities in WHO Prequalification Programme Quality Assurance and Safety: Medicines (QSM) Essential Medicines and Policy (EMP) Dr. Milan Smid
Capacity building • WHO support to development, manufacture, control or regulation of medicines Manufacturers Clinical Research Organizations (CROs) Quality control laboratories (QCLs) National Regulatory Authorities (NRAs)
Capacity building • How to manufacture according to WHO Good Manufacturing Practice (GMP) standards • How to compile a dossier for WHO Prequalification Programme • How NRAs can benefit from WHO Prequalification Programme • How to be in compliance with Good Practices for Quality Control (QC) laboratories • Relevant sources of information Stimulate submissions to WHO Prequalification Programme Stimulate submissions for prequalification of QC laboratories
Capacity building Prequalification Programme is in itself capacity building: • Learning from assessment (deficiency) letters and technical meetings • Learning from GMP and GCP inspections • Learning from WHOPARs/WHOPIRs etc
Capacity building 1) Trainings 2) Technical assistance 3) Provision of information and standards
1a) Trainings • Seminars and workshops • Often local manufacturers and national regulators together • Third parties often involved • Support to trainings organized by others • Focus on "training of trainers" • WHO training materials used, when available (GMP, GPCL))
Basic training modules • Principles of WHO prequalification of medicines • Good Manufacturing Practices (GMP) • Quality requirements for medicinal products/Assessment training • Development of pharmaceutical formulations (e.g. ped's) • Bioequivalence/BCS • Principles of WHO prequalification of QC laboratories and GPCL May be adapted to specific therapeutic areas (RH, MA, TB, HIV)
Main partners in organization of trainings in 2007/2009 • International Pharmaceutical Federation (FIP) • European Directorate for the Quality of Medicines & Healthcare (EDQM) • National Regulatory Authorities in South Africa, Tanzania, Estonia, Ukraine, Morocco, Brazil, Jordan, Ghana, Egypt, Indonesia, Kenya, Uganda, China • National Quality Control Laboratories in Morocco and Tanzania • East Africa Community (EAC) • Association of Southeast Asian Nations (ASEAN) • Ministry of Health China, Pakistan, Iran, Morocco • Program for Appropriate Technology in Health (PATH) • United Nations Population Fund (UNFPA) • European Department for Quality of Medicines (EDQM) • European Medicines Agency (EMEA) • Drug Information Association (DIA) • Therapeutic Goods Agency Australia (TGA) • Roche Pharmaceuticals
1b) Individualized trainings • Involvement of assessors from NRAs in CPH sessions • Involvement of inspectors from NRAs in PQ inspections • 3-month rotation of assessors from NRAs* at WHO HQ Capacity building of experts from NRAs (regional resource persons - improvement of NRA practices/procedures, trainings, networking, product issues) *Ethiopia, Kenya, Tanzania, Uganda, Ukraine, Zimbabwe, Ghana…
2) Technical Assistance • Provision of expert consultants to • Manufacturers • QC laboratories • Assistance focuses on • GMP, GCP or GLP compliance • Data development and compilation of dossier • Regulatory guidance • Assistance is separate from assessments/inspections and may be followed by specific training
Conditions for technical assistance Manufacturers: • Participation in the PQ programme • Capable and willing to improve • Location in a developing country Products: • Inclusion in the Invitation for Expression of Interest (EOI) • High public health value • Poorly represented on the Prequalification list.
3) Provision of information • Information related to prequalified products, or manufacturers/CROs • Prequalified lists (products, labs) and "Dossier status" • "Characteristics of prequalified product" • Public assessment reports (WHOPAR, SPC, PIL) • Public inspection reports (WHOPIR – APIs and FPPs) • Notice of concern/suspension • Guidelines and standards • Published training materials / CDs • Technical Briefing Seminars in Geneva